Tumor Control and Toxicity after SBRT for Ultracentral, Central, and Paramediastinal Lung Tumors

Ky Nam B. Nguyen, Destiny J. Hause, Jennifer Novak, Arta M Monjazeb, Megan E Daly

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Purpose: Increased rates of toxicity have been described after stereotactic body radiation therapy (SBRT) for central lung tumors within 2 cm of the proximal bronchial tree (PBT). Recent studies have defined a new class of ultracentral tumors. We report our experience treating ultracentral, central, and paramediastinal tumors with SBRT and compare toxicity, disease control, and survival rates. Methods and materials: We reviewed the records of patients with central lung tumors treated with SBRT between September 2009 and July 2017. Tumors were classified as central if within 2 cm of the PBT, ultracentral if the planning target volume touched the PBT or esophagus, and paramediastinal if touching mediastinal pleura. Actuarial rates of grades 2+ and 3+ toxicity, local control (LC), and overall survival were assessed using the Kaplan-Meier method and compared using a log-rank test. Toxicity was scored with the Common Terminology Criteria for Adverse Events, version 4.03. Results: We identified 68 patients with 69 central lung tumors, including 14 ultracentral, 15 paramediastinal, and 39 central tumors. Fifty-three patients were treated for early stage lung cancer and 15 for lung metastases. The prescribed dose ranged from 40 Gy to 60 Gy over 3 to 8 fractions. Most patients were treated using 5 fractions (83%), followed by 8 fractions (10%). Median follow-up was 19.7 months (range, 3.3-78.3 months). The 2-year estimates of LC (89%, 85%, and 93%, respectively; P =.72) and overall survival (76%, 73%, and 72%, respectively; P =.75) for ultracentral, central, and paramediastinal tumors were similar. Ultracentral tumors had an increased risk of grade 2+ toxicity (57.6% vs 14.2% vs 7.1%; P =.007) at 2 years. One patient with an ultracentral tumor developed grade 5 respiratory failure. Conclusions: The oncologic outcomes after SBRT for ultracentral, central, and paramediastinal lung tumors were similar, with LC exceeding 85% at 2 years using predominantly 5-fraction schedules. Ultracentral lung tumors were associated with an increased risk of toxicity in our patient cohort. Additional studies are needed to minimize toxicity for ultracentral tumors.

Original languageEnglish (US)
JournalPractical Radiation Oncology
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Radiotherapy
Lung
Neoplasms
Lung Neoplasms
Survival
Pleura
Terminology
Respiratory Insufficiency
Esophagus
Appointments and Schedules
Survival Rate
Neoplasm Metastasis

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Tumor Control and Toxicity after SBRT for Ultracentral, Central, and Paramediastinal Lung Tumors. / Nguyen, Ky Nam B.; Hause, Destiny J.; Novak, Jennifer; Monjazeb, Arta M; Daly, Megan E.

In: Practical Radiation Oncology, 01.01.2019.

Research output: Contribution to journalArticle

@article{b3a3968ac8e644f98fee7c622bada6ea,
title = "Tumor Control and Toxicity after SBRT for Ultracentral, Central, and Paramediastinal Lung Tumors",
abstract = "Purpose: Increased rates of toxicity have been described after stereotactic body radiation therapy (SBRT) for central lung tumors within 2 cm of the proximal bronchial tree (PBT). Recent studies have defined a new class of ultracentral tumors. We report our experience treating ultracentral, central, and paramediastinal tumors with SBRT and compare toxicity, disease control, and survival rates. Methods and materials: We reviewed the records of patients with central lung tumors treated with SBRT between September 2009 and July 2017. Tumors were classified as central if within 2 cm of the PBT, ultracentral if the planning target volume touched the PBT or esophagus, and paramediastinal if touching mediastinal pleura. Actuarial rates of grades 2+ and 3+ toxicity, local control (LC), and overall survival were assessed using the Kaplan-Meier method and compared using a log-rank test. Toxicity was scored with the Common Terminology Criteria for Adverse Events, version 4.03. Results: We identified 68 patients with 69 central lung tumors, including 14 ultracentral, 15 paramediastinal, and 39 central tumors. Fifty-three patients were treated for early stage lung cancer and 15 for lung metastases. The prescribed dose ranged from 40 Gy to 60 Gy over 3 to 8 fractions. Most patients were treated using 5 fractions (83{\%}), followed by 8 fractions (10{\%}). Median follow-up was 19.7 months (range, 3.3-78.3 months). The 2-year estimates of LC (89{\%}, 85{\%}, and 93{\%}, respectively; P =.72) and overall survival (76{\%}, 73{\%}, and 72{\%}, respectively; P =.75) for ultracentral, central, and paramediastinal tumors were similar. Ultracentral tumors had an increased risk of grade 2+ toxicity (57.6{\%} vs 14.2{\%} vs 7.1{\%}; P =.007) at 2 years. One patient with an ultracentral tumor developed grade 5 respiratory failure. Conclusions: The oncologic outcomes after SBRT for ultracentral, central, and paramediastinal lung tumors were similar, with LC exceeding 85{\%} at 2 years using predominantly 5-fraction schedules. Ultracentral lung tumors were associated with an increased risk of toxicity in our patient cohort. Additional studies are needed to minimize toxicity for ultracentral tumors.",
author = "Nguyen, {Ky Nam B.} and Hause, {Destiny J.} and Jennifer Novak and Monjazeb, {Arta M} and Daly, {Megan E}",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.prro.2018.11.005",
language = "English (US)",
journal = "Practical Radiation Oncology",
issn = "1879-8500",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Tumor Control and Toxicity after SBRT for Ultracentral, Central, and Paramediastinal Lung Tumors

AU - Nguyen, Ky Nam B.

AU - Hause, Destiny J.

AU - Novak, Jennifer

AU - Monjazeb, Arta M

AU - Daly, Megan E

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Purpose: Increased rates of toxicity have been described after stereotactic body radiation therapy (SBRT) for central lung tumors within 2 cm of the proximal bronchial tree (PBT). Recent studies have defined a new class of ultracentral tumors. We report our experience treating ultracentral, central, and paramediastinal tumors with SBRT and compare toxicity, disease control, and survival rates. Methods and materials: We reviewed the records of patients with central lung tumors treated with SBRT between September 2009 and July 2017. Tumors were classified as central if within 2 cm of the PBT, ultracentral if the planning target volume touched the PBT or esophagus, and paramediastinal if touching mediastinal pleura. Actuarial rates of grades 2+ and 3+ toxicity, local control (LC), and overall survival were assessed using the Kaplan-Meier method and compared using a log-rank test. Toxicity was scored with the Common Terminology Criteria for Adverse Events, version 4.03. Results: We identified 68 patients with 69 central lung tumors, including 14 ultracentral, 15 paramediastinal, and 39 central tumors. Fifty-three patients were treated for early stage lung cancer and 15 for lung metastases. The prescribed dose ranged from 40 Gy to 60 Gy over 3 to 8 fractions. Most patients were treated using 5 fractions (83%), followed by 8 fractions (10%). Median follow-up was 19.7 months (range, 3.3-78.3 months). The 2-year estimates of LC (89%, 85%, and 93%, respectively; P =.72) and overall survival (76%, 73%, and 72%, respectively; P =.75) for ultracentral, central, and paramediastinal tumors were similar. Ultracentral tumors had an increased risk of grade 2+ toxicity (57.6% vs 14.2% vs 7.1%; P =.007) at 2 years. One patient with an ultracentral tumor developed grade 5 respiratory failure. Conclusions: The oncologic outcomes after SBRT for ultracentral, central, and paramediastinal lung tumors were similar, with LC exceeding 85% at 2 years using predominantly 5-fraction schedules. Ultracentral lung tumors were associated with an increased risk of toxicity in our patient cohort. Additional studies are needed to minimize toxicity for ultracentral tumors.

AB - Purpose: Increased rates of toxicity have been described after stereotactic body radiation therapy (SBRT) for central lung tumors within 2 cm of the proximal bronchial tree (PBT). Recent studies have defined a new class of ultracentral tumors. We report our experience treating ultracentral, central, and paramediastinal tumors with SBRT and compare toxicity, disease control, and survival rates. Methods and materials: We reviewed the records of patients with central lung tumors treated with SBRT between September 2009 and July 2017. Tumors were classified as central if within 2 cm of the PBT, ultracentral if the planning target volume touched the PBT or esophagus, and paramediastinal if touching mediastinal pleura. Actuarial rates of grades 2+ and 3+ toxicity, local control (LC), and overall survival were assessed using the Kaplan-Meier method and compared using a log-rank test. Toxicity was scored with the Common Terminology Criteria for Adverse Events, version 4.03. Results: We identified 68 patients with 69 central lung tumors, including 14 ultracentral, 15 paramediastinal, and 39 central tumors. Fifty-three patients were treated for early stage lung cancer and 15 for lung metastases. The prescribed dose ranged from 40 Gy to 60 Gy over 3 to 8 fractions. Most patients were treated using 5 fractions (83%), followed by 8 fractions (10%). Median follow-up was 19.7 months (range, 3.3-78.3 months). The 2-year estimates of LC (89%, 85%, and 93%, respectively; P =.72) and overall survival (76%, 73%, and 72%, respectively; P =.75) for ultracentral, central, and paramediastinal tumors were similar. Ultracentral tumors had an increased risk of grade 2+ toxicity (57.6% vs 14.2% vs 7.1%; P =.007) at 2 years. One patient with an ultracentral tumor developed grade 5 respiratory failure. Conclusions: The oncologic outcomes after SBRT for ultracentral, central, and paramediastinal lung tumors were similar, with LC exceeding 85% at 2 years using predominantly 5-fraction schedules. Ultracentral lung tumors were associated with an increased risk of toxicity in our patient cohort. Additional studies are needed to minimize toxicity for ultracentral tumors.

UR - http://www.scopus.com/inward/record.url?scp=85059772037&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059772037&partnerID=8YFLogxK

U2 - 10.1016/j.prro.2018.11.005

DO - 10.1016/j.prro.2018.11.005

M3 - Article

C2 - 30496842

AN - SCOPUS:85059772037

JO - Practical Radiation Oncology

JF - Practical Radiation Oncology

SN - 1879-8500

ER -